🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

482 results for “60” Clear

  1. Temozolomide Accord 180 mg hard capsules., Temozolomide Accord 250 mg hard capsules., Temozolomide Accord 5 mg hard capsules., Temozolomide SUN 5 mg hard capsules, Temozolomide Accord 20 mg hard capsules., Temozolomide SUN 180 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide Accord 100 mg hard capsules., Temozolomide SUN 140 mg hard capsules, Temozolomide Accord 140 mg hard capsules., Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 20 mg hard capsules

    Disc Medicine

    Diffuse Midline Glioma, H3K27-altered

    phase 2 small molecule active

    1 trial

  2. Thiogamma 600 mg Filmtabletten, Benfogamma Forte, 300 mg, tabletki powlekane

    Lacuna Pharma Pty Ltd

    Diabetic sensorimotor polyneuropathy (DSPN)

    phase 2 small molecule active

    1 trial

  3. Tolinapant, Tolinapant

    Taiho Pharma Netherlands B.V.

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

  4. Ultravist 370 mg/ml soluzione iniettabile

    Istituto Gentili S.r.l.

    Patients with breast lesions undergoing further examination

    phase 2 small molecule active

    1 trial

  5. VS-6766, VS-6063

    Vera Therapeutics

    Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

    phase 2 small molecule active

    1 trial

  6. Vacuna Dermatophagoides mezcla Placebo, Vacuna Dermatophagoides mezcla 3000 TBU/ml, Test de provocación nasal, Vacuna Dermatophagoides mezcla 6000 TBU/ml, Vacuna Dermatophagoides mezcla 1000 TBU/ml

    Advanced Accelerator Applications

    Allergic rhinitis/rhinoconjunctivitis caused by dust mite allergy

    phase 2 small molecule active

    1 trial

  7. Venclyxto 50 mg film-coated tablets, JNJ-54179060, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, IMBRUVICA 140 mg hard capsules

    Janssen-Cilag International N.V.

    Untreated Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  8. Vi-Siblin S granulat, alli 60 mg hard capsules, Dietary fibre supplement Placebo - Maltodextrin

    Lacuna Pharma Pty Ltd

    Obesity

    phase 2 small molecule active

    1 trial

  9. Xeloda 150 mg film-coated tablets, Folinic acid (as calcium folinate) 10 mg/ml solution for injection/infusion, ELOXATINE 5 mg/ml, solution à diluer pour perfusion, Vectibix 20 mg/ml concentrate for solution for infusion, FLUOROURACILE TEVA 1000 mg/20 ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    metastatic colorectal adenocarcinoma

    phase 2 small molecule active

    1 trial

  10. Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Gilteritinib, ARA-cell® 40 mg Injektion 20 mg/ml Injektionslösung / Konzentrat zur Herstellung einer Infusionslösung, Gilteritinib, Bendarabin 50 mg Pulver zur Herstellung einer Injektions- oder Infusionslösung, Citarabina Hikma 1 g/10mL Soluzione Iniettabile

    Astellas Pharma GmbH

    FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  11. [177Lu]-NeoB solution for infusion, AAA503

    Advanced Accelerator Applications

    Solid tumors known to overexpress GRPR and with [68Ga]-NeoB lesion uptake.

    phase 2 small molecule active

    1 trial

  12. [18F]Tetrafluoroborate

    Disc Medicine

    Differentiated Thyroid Cancer

    phase 2 small molecule active

    1 trial

  13. ecallantide 60 mg

    Takeda

    ACE Inhibitor Induced Angioedema

    phase 2 small molecule terminated

    1 trial

  14. efinopegdutide, efinopegdutide, efinopegdutide, Placebo to MK-6024, efinopegdutide

    Merck Sharp and Dohme

    Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  15. elafibranor, Placebo of Elafibranor, elafibranor

    Ipsen

    Primary Sclerosing Cholangitis

    phase 2 small molecule active

    1 trial

  16. inhaled delta-8-THC 300mcg or 600mcg per dose

    Teva Pharma GmbH

    Cancer

    phase 2 small molecule terminated

    1 trial

  17. pazopanib (GW786034)

    GlaxoSmithKline

    Neoplasms, Uterine Cervix

    phase 2 small molecule completed

    1 trial

  18. pazopanib (GW786034) 400 mg

    GlaxoSmithKline

    Neoplasms, Breast

    phase 2 small molecule completed

    1 trial

  19. 500 mg [14C]-LX1606

    LEXICON PHARMACEUTICALS, INC.

    Carcinoid Syndrome

    phase 1 small molecule completed

    1 trial

  20. 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  21. 608

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Moderate to Severe Plaque Psoriasis

    phase 1 small molecule active

    1 trial

  22. 609A

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Solid Tumors

    phase 1 small molecule active

    2 trials

  23. A Clinical Study to Compare the Impact of Multiple-dose Oral Administration of Macitentan, 10 mg versus 75 mg on Endothelin-1 Clearance, Endothelial Function, and Hemodynamics in Healthy Participants

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension

    phase 1 other active

    1 trial

  24. A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent.

    Novartis Pharmaceuticals

    Glioblastoma

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources